Aquinnah Pharmaceuticals

Aquinnah Pharmaceuticals is a privately held biopharmaceutical company based in Cambridge, Massachusetts, in the United States. The company is focused on a bold new approach to neurodegenerative disease: rather than targeting a single misfolded protein, it aims to remove the pathologic biomolecular condensates — including stress granules — that contribute to disease progression in amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), Alzheimer's disease, and other neurological disorders. The scientific foundation of Aquinnah rests on the work of Dr. Benjamin Wolozin, M.D., Ph.D., the company's Chief Scientific Officer and co-founder. Dr. Wolozin pioneered the connection between stress granules and neurodegenerative diseases, a discovery now recognized as one of the most important in the field. Aquinnah's technology leverages deep expertise in the interplay of RNA-binding proteins that form biomolecular condensates, allowing the company to identify and develop new innovative small-molecule therapeutics administered as a pill. Aquinnah has reported preclinical research on its novel therapeutic demonstrating potential for a new drug approach for Alzheimer's disease, with a reduction of brain tau pathology of approximately 70%. The company has garnered support from major pharmaceutical companies including AbbVie, Pfizer, and Takeda, in addition to securing numerous peer-reviewed grants from the National Institute of Health. This combination of industry backing and public research funding supports its drug-discovery programs. As a clinical-stage-oriented discovery company, Aquinnah positions itself at the intersection of RNA biology, condensate science, and neurology. Its stated mission addresses the pressing unmet medical need for effective neurodegenerative disease treatments, an area where few disease-modifying oral therapies exist. The company remains privately held and operates primarily in the United States, with its research and corporate base in Cambridge, Massachusetts.

Aquinnah Pharmaceuticals is a Cambridge, Massachusetts-based biopharmaceutical company built around a scientific insight from its co-founder and Chief Scientific Officer, Dr. Benjamin Wolozin, M.D., Ph.D. Dr. Wolozin pioneered the connection between stress granules and neurodegenerative diseases, a discovery now recognized as one of the most important in the field. That insight became the foundation of Aquinnah's therapeutic strategy. The company's approach centers on biomolecular condensates — dynamic assemblies of RNA-binding proteins that can form stress granules. In neurodegenerative disease, pathologic condensates containing particularly "sticky" proteins are thought to contribute to disease progression. Aquinnah's technology leverages expertise in the interplay of RNA-binding proteins to identify and develop small-molecule therapeutics, administered as a pill, designed to remove these pathologic condensates. Aquinnah has targeted its technology at amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), Alzheimer's disease, and other neurological disorders. The company has reported preclinical research on its novel therapeutic demonstrating potential for a new drug approach for Alzheimer's disease, reducing brain tau pathology by approximately 70%. This result was presented by Dr. Wolozin and publicized through the company's news channels. Support for Aquinnah's programs has come from both industry and government sources. The company states that it has garnered support from major pharmaceutical companies including AbbVie, Pfizer, and Takeda, in addition to securing numerous peer-reviewed grants from the National Institute of Health. This mix of corporate collaboration and peer-reviewed public funding has helped sustain its discovery-stage research. As of the available evidence, Aquinnah remains a privately held company headquartered in Cambridge, Massachusetts, in the United States. It continues to position itself as a pioneer in condensate biology for neurology, pursuing oral small-molecule therapies for diseases with substantial unmet medical need.

• Dr. Benjamin Wolozin pioneers the connection between stress granules and neurodegenerative diseases, forming the scientific basis of Aquinnah.

• Aquinnah reports preclinical research showing its novel therapeutic reduces brain tau pathology by approximately 70% in Alzheimer's disease models.

• Aquinnah secures support from major pharmaceutical companies including AbbVie, Pfizer, and Takeda, along with peer-reviewed grants from the National Institute of Health.

A discovery-stage biopharmaceutical company pioneering stress-granule and biomolecular-condensate science to develop oral small-molecule treatments for ALS, Alzheimer's disease, and other neurological disorders.

• Oral small-molecule therapeutic targeting pathologic biomolecular condensates

  A pill-administered small-molecule drug candidate designed to remove pathologic condensates, including stress granules, implicated in ALS, Alzheimer's disease, and other neurological disorders.

1. 1Aquinnah Pharmaceuticals official websiteaquinnahpharma.com
2. 2Wikidata: Aquinnah (United States)wikidata.org